










































Immunogenicity and pathogenicity of chimeric infectious DNA
clones of pathogenic porcine circovirus type 2 (PCV2) and
nonpathogenic PCV1 in weanling pigs
Citation for published version:
Fenaux, M, Meng, XJ, Opriessnig, T & Halbur, PG 2003, 'Immunogenicity and pathogenicity of chimeric
infectious DNA clones of pathogenic porcine circovirus type 2 (PCV2) and nonpathogenic PCV1 in weanling
pigs' Journal of Virology, vol. 77, no. 20, pp. 11232-11243. DOI: 10.1128/JVI.77.20.11232-11243.2003
Digital Object Identifier (DOI):
10.1128/JVI.77.20.11232-11243.2003
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright © 2003, American Society for Microbiology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
JOURNAL OF VIROLOGY, Oct. 2003, p. 11232–11243 Vol. 77, No. 20
0022-538X/03/$08.000 DOI: 10.1128/JVI.77.20.11232–11243.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Immunogenicity and Pathogenicity of Chimeric Infectious DNA Clones
of Pathogenic Porcine Circovirus Type 2 (PCV2) and Nonpathogenic
PCV1 in Weanling Pigs
M. Fenaux,1 T. Opriessnig,2 P. G. Halbur,2 and X. J. Meng1*
Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, College
of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061-0342,1
and Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine,
Iowa State University, Ames, Iowa 500112
Received 16 May 2003/Accepted 18 July 2003
Porcine circovirus type 2 (PCV2) is the primary causative agent of postweaning multisystemic wasting
syndrome (PMWS), whereas the ubiquitous porcine circovirus type 1 (PCV1) is nonpathogenic for pigs. We
report here the construction and characterization of two chimeric infectious DNA clones of PCV1 and PCV2.
The chimeric PCV1-2 clone contains the PCV2 capsid gene cloned in the backbone of the nonpathogenic PCV1
genome. A reciprocal chimeric PCV2-1 DNA clone was also constructed by replacing the PCV2 capsid gene with
that of PCV1 in the backbone of the PCV2 genome. The PCV1, PCV2, and chimeric PCV1-2 and PCV2-1 DNA
clones were all shown to be infectious in PK-15 cells, and their growth characteristics in vitro were determined
and compared. To evaluate the immunogenicity and pathogenicity of the chimeric infectious DNA clones, 40
specific-pathogen-free (SPF) pigs were randomly assigned into five groups of eight pigs each. Group 1 pigs
received phosphate-buffered saline as the negative control. Group 2 pigs were each injected in the superficial
inguinal lymph nodes with 200 g of the PCV1 infectious DNA clone. Group 3 pigs were each similarly injected
with 200 g of the PCV2 infectious DNA clone, group 4 pigs were each injected with 200 g of the chimeric
PCV1-2 infectious DNA clone, and group 5 pigs were each injected with 200 g of the reciprocal chimeric
PCV2-1 infectious DNA clone. As expected, seroconversion to antibodies to the PCV2 capsid antigen was
detected in group 3 and group 4 pigs. Group 2 and 5 pigs all seroconverted to PCV1 antibody. Gross and
microscopic lesions in various tissues of animals inoculated with the PCV2 infectious DNA clone were
significantly more severe than those found in pigs inoculated with PCV1, chimeric PCV1-2, and reciprocal
chimeric PCV2-1 infectious DNA clones. These data indicated that the chimeric PCV1-2 virus with the
immunogenic ORF2 capsid gene of pathogenic PCV2 cloned into the nonpathogenic PCV1 genomic backbone
induces a specific antibody response to the pathogenic PCV2 capsid antigen but is attenuated in pigs. Future
studies are warranted to evaluate the usefulness of the chimeric PCV1-2 infectious DNA clone as a genetically
engineered live-attenuated vaccine against PCV2 infection and PMWS.
Porcine circovirus (PCV) was first discovered as a noncyto-
pathic contaminant of the porcine kidney cell culture PK-15
(62, 66). PCV is a small icosahedral nonenveloped virus with a
single-stranded circular DNA genome of about 1.76 kb. The
PCV genome contains at least two potentially functional open
reading frames (ORFs): ORF1 (930 bp) encodes the Rep
protein involved in viral replication and ORF2 (690 bp) en-
codes the immunogenic capsid protein (15, 23, 39, 49). PCV
belongs to the Circoviridae family along with other animal
circoviruses such as Psittacine beak and feather disease virus,
Chicken anemia virus (13), and Columbid circovirus (40). There
are also three plant circoviruses, banana bunchy top virus,
coconut foliar decay virus, and subterranean clover stunt virus
(13, 42). Recently, three novel human circoviruses have been
discovered, including transfusion-transmitted virus (TTV),
SEN virus, and TTV-like minivirus (14, 44, 45, 51, 61, 67, 70).
Although antibodies to PCV have been found in many animal
species including humans, mice, cattle, and pigs (1, 17, 18, 30,
43, 50, 64, 65), little is known regarding the pathogenesis of
PCV in these animal species (55, 65). The PK-15-derived PCV
did not produce clinical disease in experimentally inoculated
pigs, and thus the virus was considered to be nonpathogenic (3,
63) and was designated PCV1.
Postweaning multisystemic wasting syndrome (PMWS) is an
emerging disease in pigs first described in 1991 (27). PMWS
primarily affects pigs between 5 and 18 weeks of age. Clinical
PMWS signs include progressive weight loss, dyspnea, tachy-
pnea, anemia, diarrhea, and jaundice. The mortality rate may
vary from 1 to 2% and up to 40% in some complicated cases in
the United Kingdom (47). Characteristics of PMWS include
microscopic lesions, granulomatous interstitial pneumonia,
lymphadenopathy, hepatitis, and nephritis (4, 8, 11, 27). PMWS
has now been recognized in pigs in Canada, the United States
(5, 19, 26, 30, 34, 38, 46), most European countries (5, 11, 18,
32, 36, 39, 56, 60, 68), and some countries in Asia (16, 52).
PMWS potentially has a serious economic impact on the swine
industry worldwide.
The primary causative agent of PMWS is a pathogenic strain
of PCV designated PCV2 (2, 5, 9, 11, 19, 21, 22, 23, 43, 46). The
complete genomic sequence of PMWS-associated PCV2 has
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been determined (23, 26, 41). Sequence analyses revealed that
PMWS-associated PCV2 shares about 75% nucleotide se-
quence identity with the nonpathogenic PCV1. The pathogenic
PCV2 shares a very similar genomic organization with the
nonpathogenic PCV1. The ORF2 gene of both PCV1 and
PCV2 encodes the major immunogenic capsid protein (15, 48,
49). Initial attempts to reproduce clinical PMWS in conven-
tional pigs by PCV2 inoculation were unsuccessful (12, 22, 33).
Recently, clinical PMWS was reproduced in cesarean-derived–
colostrum-deprived pigs and in specific-pathogen-free (SPF)
pigs inoculated with PCV2 alone (28, 37). Clinical PMWS was
also reproduced in conventional pigs coinfected with PCV2
and either porcine parvovirus (PPV) or porcine reproductive
and respiratory syndrome virus (PRRSV) (57; T. Opriessnig,
M. Fenaux, S. Yu, R. B. Evans, D. Cavanaugh, J. M. Gallup,
F. J. Pallares, E. L. Thacker, K. M. Lagger, X. J. Meng, and
P. G. Halbur, submitted for publication). In addition, PMWS
was reproduced in PCV2-inoculated gnotobiotic pigs when
their immune system was activated by keyhole limpet hemocy-
anin in incomplete Freund’s adjuvant (35; A. Bøtner, S. Ladek-
jaer-Mikkelsen, J. Nielsen, S. Krakowka, J. Ellis, F. McNeilly,
G. Allan, and Y. Storgard, Proc. Conf. ssDNA Viruses Plants
Birds Pigs Primates, p. 132, 2002). Two recent field studies by
Allan et al. (7) and Kyriakis et al. (36) tested the effect of
immunomodulation by Mycoplasma hyopneumoniae vaccine on
the development of PMWS in herds in which the disease is
endemic and showed a significant decrease in PMWS cases in
unvaccinated groups compared to the vaccinated animals.
However, a controlled laboratory study by Opriessnig et al.
(53) was able to induce significantly longer viremia and more
severe lymphoid lesions but was not able to reproduce clinical
PMWS in M. hyopneumoniae- and Actinobacillus pleuropneu-
moniae-vaccinated and PCV2-inoculated SPF piglets. Taken
together, PCV2 is generally considered to be the primary, but
not the sole, causative agent of PMWS.
It was previously shown that the cloned genomic DNA of
PCV2 is infectious when directly injected into the liver and
lymph nodes of pigs (22) and that the infectious PCV2 DNA
clone produced pathological lesions characteristic of PMWS in
SPF pigs (22). Here in this study, we report for the first time
that chimeric DNA clones of PCV1 and PCV2 are infectious
when transfected into PK-15 cells and express respective cap-
sid antigen and are also infectious when injected directly into
the superficial inguinal lymph nodes of SPF piglets. The im-
munogenicity and pathogenicity of the chimeric infectious
DNA clones were characterized in pigs.
MATERIALS AND METHODS
Cell and virus. The PK-15 cell line used in this study (ATCC CCL-33) was free
of PCV1 contamination, as generated by endpoint dilutions (22). The PCV1 virus
used in the study originated from the contaminated ATCC PK-15 cell line (63,
66). The PCV2 virus used in the study was originally isolated from a spleen tissue
sample of a pig with naturally occurring PMWS (22, 23). The PCV2 infectious
DNA clone was described previously (22).
Construction of the nonpathogenic PCV1 infectious DNA clone. The proce-
dure used for the construction of the PCV1 infectious DNA clone is very similar
to that for PCV2 (22). Briefly, the primers KPNPCV1.U and KPNPCV1.L
(Table 1) were designed based on the published sequence of PCV1 (42) to
amplify the complete PCV1 genome, as a 1,758-bp PCR product, with an over-
lapping region containing the unique KpnI restriction enzyme site. The PCV1
DNA was extracted from PK-15 cells (ATCC CCL-33) persistently infected with
PCV1, by using the QIAmp DNA minikit (Qiagen, Inc., Valencia, Calif.). The
extracted DNA was amplified by PCR with Amplitaq Gold polymerase (Perkin-
Elmer, Norwalk, Conn.). The PCR cycles consisted of an initial step of 95°C for
10 min, followed by 35 cycles of denaturation at 94°C for 1 min, annealing at 48°C
for 1 min, and extension at 72°C for 2 min, and a final extension at 72°C for 7 min.
The PCR product of the expected size was separated by gel electrophoresis,
purified using a Geneclean kit (Bio 101, Inc., La Jolla, Calif.), digested by the
KpnI restriction enzyme, and cloned into pBluescript SK (pSK) vector (Strat-
agene, La Jolla, Calif.). Escherichia coli DH5 competent cells were used for
transformation. Recombinant plasmids containing the full-length PCV1 genome
were isolated with a Qiagen plasmid minikit and were verified by restriction
enzyme digestion. The full-length PCV1 genome was excised from the pSK
vector by KpnI digestion and dimerized as described previously for the PCV2
infectious DNA clone (22) to produce the PCV1 infectious DNA clone. Based on
previous data (22), the dimerized tandem DNA clone is more efficient in trans-
TABLE 1. Oligonucleotide primers used in this study
Primer Primer sequence Application
KPNPCV1.U. a 5-TTTGGTACCCGAAGGCCGATT-3 PCV1 DNA clone construction
KPNPCV1.L.  5-ATTGGTACCTCCGTGGATTGTTCT-3 PCV1 DNA clone construction
HpaI-2  5-GAAGTTAACCCTAAATGAATAAAAATAAAAACCATTACG-3 PCV1-2 DNA clone construction
NarI-3  5-GGTGGCGCCTCCTTGGATACGTCATCCTATAAAAGTG-3 PCV1-2 DNA clone construction
PsiI-5  5-AGGTTATAAGTGGGGGGTCTTTAAGATTAA-3 PCV1-2 DNA clone construction
AclI-6  5-GGAAACGTTACCGCAGAAGAAGACACC-3 PCV1-2 DNA clone construction
BglII-ORF2  5-ACTATAGATCTTTATTCATTTAGAGGGTCTTTCAG-3 PCV2-1 DNA clone construction
SphI-ORF2  5-TACGGGCATGCATGACGTGGCCAAGGAGG-3 PCV2-1 DNA clone construction
BglII-PCV2  5-AGACGAGATCTATGAATAATAAAAACCATTACGAAG-3 PCV2-1 DNA clone construction
SphI-PCV2  5-CGTAAGCATGCAGCTGAAAACGAAAGAAGTG-3 PCV2-1 DNA clone construction
MCV1  5-GCTGAACTTTTGAAAGTGAGCGGG-3 PCV1 and PCV2 detection
MCV2  5-TCACACAGTCTCAGTAGATCATCCCA-3 PCV1 and PCV2 detection
Orf.PCV1  5-CCAACTTTGTAACCCCCTCCA-3 PCV1 and PCV2-1 detection
Gen.PCV1  5-GTGGACCCACCCTGTGCC-3 PCV1 and PCV1-2 detection
nested.Orf.PCV1  5-CCAGCTGTGGCTCCATTTAA-3 PCV1 and PCV2-1 detection
nested.Gen.PCV1  5-TTCCCATATAAAATAAATTACTGAGTCTT-3 PCV1 and PCV1-2 detection
Orf.PCV2  5-CAGTCAGAACGCCCTCCTG-3 PCV2 and PCV1-2 detection
Gen.PCV2  5-CCTAGAAACAAGTGGTGGGATG-3 PCV2 and PCV2-1 detection
nested.Orf.PCV2  5-TTGTAACAAAGGCCACAGC-3 PCV2 and PCV1-2 detection
nested.Gen.PCV2  5-GTGTGATCGATATCCATTGACTG-3 PCV2 and PCV2-1 detection
a Primer direction.
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fecting cells and producing infectious virions than the clone containing a single
copy of the viral genome.
Construction of a chimeric PCV1-2 infectious DNA clone. The ORF2 gene of
both PCV1 and PCV2 encodes the immunogenic viral capsid protein (49). To
construct a chimeric PCV1-2 DNA clone, the ORF2 capsid gene of PCV1 was
replaced with that of the pathogenic PCV2 in the genome backbone of PCV1
(Fig. 1). Briefly, two pairs of PCR primers were designed: the first pair, PsiI-5 and
AclI-6, amplified the PCV2 ORF2 gene, a fragment of 693 bp, and introduced
flanking PsiI and AclI restriction enzyme sites by point mutations. The PCR for
the amplification of PCV2 ORF2 consisted of an initial step at 95°C for 9 min,
followed by 38 cycles of denaturation at 95°C for 1 min, annealing at 48°C for 1
min, extension at 72°C for 1 min, and a final extension at 72°C for 7 min. The
second PCR primer pair, HpaI-2 and NarI-3, amplified the pSK vector and the
PCV1 genome without the PCV1 ORF2 (pSK-PCV1 ORF2), a fragment of
4,023 bp, by using the PCV1 infectious DNA clone as the PCR template, and
introduced flanking restriction enzyme sites HpaI and NarI by point mutations.
The PCR consisted of an initial step at 95°C for 9 min, followed by 38 cycles of
denaturation at 95°C for 1 min, annealing at 50°C for 1 min, extension at 72°C for
3.5 min, and a final extension at 72°C for 7 min. The pSK-PCV1 ORF2 PCR
product was digested by HpaI and NarI to produce a sticky end and a blunt end
FIG. 1. Organization of the infectious DNA clones. The PCV2 DNA clone was constructed by ligating two full-length linear PCV2 genomes
in tandem into pSK as described previously (22). The PCV1 DNA clone was constructed by ligating two full-length linear PCV1 genomes in tandem
into pSK. The chimeric PCV1-2 DNA clone was constructed by replacing the ORF2 capsid gene of PCV1 with that of PCV2 in the nonpathogenic
PCV1 genomic backbone in pSK. The reciprocal chimeric PCV2-1 DNA clone was constructed by replacing the ORF2 capsid gene of the
pathogenic PCV2 with that of the nonpathogenic PCV1 in the PCV2 genomic backbone in pSK. Both chimeric clones were dimers in pSK. The
arrows represent the relative locations of the PCR primers used for the detection of PCV1, PCV2, PCV1-2, and PCV2-1 viremia in inoculated
animals.
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complementary to the PCV2 ORF2 PCR product digested by AclI and PsiI
restriction enzymes. Once the two PCR products were digested and ligated, all
the PCR-introduced point mutations used to facilitate cloning steps were re-
moved in the resulting chimeric DNA clone. E. coli DH5 competent cells were
transformed. The recombinant plasmids containing the chimeric PCV1-2 DNA
clone were isolated and were verified by restriction enzyme digestion and partial
DNA sequencing. The full-length chimeric PCV1-2 genome was excised from the
recombinant plasmid by KpnI digestion and dimerized (22) to produce the
PCV1-2 chimeric infectious DNA clone (Fig. 1).
Construction of a reciprocal chimeric PCV2-1 infectious DNA clone. To con-
struct a reciprocal PCV2-1 chimeric DNA clone, the ORF2 capsid gene of PCV2
was replaced by that of the nonpathogenic PCV1 in the genome backbone of the
pathogenic PCV2 (Fig. 1). Briefly, two PCR primer pairs were designed: the first
pair, BglII-ORF2 and SphI-ORF2, amplified the PCV1 ORF2 gene, a fragment
of 690 bp, and introduced flanking BglII and SphI restriction enzyme sites by
point mutations. The second PCR primer pair, BglII-PCV2 and SphI-PCV2,
amplified the pSK vector and the PCV2 genome without the ORF2 gene (pSK-
PCV2 ORF2), a fragment of 4,030 bp, by using the PCV2 infectious DNA clone
as the PCR template, and introduced flanking restriction enzymes sites BglII and
SphI by point mutations. The pSK-PCV2 ORF2 product and the PCV1 ORF2
PCR product were digested by BglII and SphI restriction enzymes to produce
complementary sticky and blunt ends and subsequently ligated together. After
transformation into E. coli cells, the authentic recombinant plasmids were iso-
lated and confirmed by enzyme digestion and partial DNA sequencing. The
full-length reciprocal chimeric PCV2-1 genome was excised from the recombi-
nant plasmid by SacII digestion and dimerized (22) to produce the reciprocal
chimeric PCV2-1 infectious DNA clone.
In vitro transfection of PK-15 cells with PCV1, PCV2, chimeric PCV1-2, and
reciprocal chimeric PCV2-1 DNA clones. The infectivity of the PCV2 DNA clone
has already been demonstrated both in vitro and in vivo (22). To test the
infectivity of the PCV1 and two chimeric clones in vitro, PK-15 cells free of PCV1
contamination (22) were grown in eight-well LabTek chamber slides (Nalge
Nunc International, Roskilde, Denmark). When the PK-15 cells reached about
80% confluency, cells were transfected with PCV1, PCV2 (22), PCV1-2, and
PCV2-1 DNA clones by using the Lipofectamine Plus reagent according to the
protocols supplied by the manufacturer (Life Technologies, Inc.). Mock-trans-
fected cells with pSK vector alone were included as controls. Three days after
transfection, the cells were fixed with a solution containing 80% acetone and
20% methanol at 4°C for 20 min. Evidence of viral capsid protein expression was
confirmed in cells transfected with the PCV1 and PCV2-1 DNA clones by
indirect immunofluorescence assay (IFA) with monoclonal antibody to the PCV1
ORF2 capsid gene (1). Briefly, the fixed cells were washed with phosphate-
buffered saline (PBS) and incubated with a diluted PCV1 monoclonal antibody
at 37°C for 1 h. The cells were then washed three times with PBS buffer and
incubated with fluorescein isothiocyanate (FITC)-labeled goat anti-mouse im-
munoglobulin G (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) at
37°C for 45 min. After being washed three times with PBS buffer, the slides were
mounted with Fluoromount-G, coverslipped, and examined under a fluorescence
microscope. The infectivity of cells transfected with the PCV2 and the chimeric
PCV1-2 DNA clones was confirmed by IFA with antibody specific for PCV2, as
previously described (22).
Transfection and subsequent serial passages of PCV1, PCV2, PCV1-2 and
PCV2-1 infectious DNA clones in PK-15 cells. In order to compare transfection
efficiencies of each PCV DNA clone in vitro and to determine the viability of
subsequent progeny viruses, four synchronized PK-15 cell cultures in T-25 flasks
were transfected each with 44 g of the PCV1, PCV2, PCV1-2, or PCV2-1 DNA
clone. The transfected cell cultures were grown to confluency and then serially
passaged five times. At each passage, 1 ml of the suspended cells was harvested,
frozen, and thawed three times. The virus titers at each passage were determined
according to the Ka¨rber method. Briefly, serial 10-fold dilutions of the samples
were used to inoculate PK-15 cells grown on eight-well LabTek chamber slides.
After 3 days of incubation, the infected PK-15 cells were fixed, and the virus titers
were determined by IFA with PCV1- or PCV2-specific antibodies according to
the same IFA protocols described above.
One-step growth curves of PCV1, PCV2, PCV1-2, and PCV2-1 viruses in
PK-15 cells. PCV1-free PK-15 cells were grown on four 12-well plates. Each
plate was infected with PCV1, PCV2, PCV1-2, and PCV2-1 live virus, respec-
tively, at a multiplicity of infection (MOI) of 0.1 per well. After 1 h of incubation,
the viral inoculum was removed and the cell monolayer was washed five times
each with 2 ml of PBS buffer. Maintenance medium (2% bovine calf serum and
1 antibiotics) was subsequently added to each well, and the infected cells were
continuously incubated at 37°C. Every 12 h, the medium and cells from one well
of each inoculation group were harvested and frozen down at 	80°C until virus
titration. The PCV1, PCV2, PCV1-2, and PCV2-1 virus infectious titers at dif-
ferent time points were determined by IFA specific for detecting PCV1 or PCV2
as described above by the Ka¨rber method.
Experimental inoculation of pigs with PCV1, PCV2, chimeric PCV1-2, and
reciprocal chimeric PCV2-1 DNA clones. Forty SPF pigs, 3 to 4 weeks of age,
were randomly assigned into five rooms of eight animals each. Pregnant sows,
from which the piglets used in this study were derived, were negative for anti-
bodies to PCV, PRRSV, PPV, or swine hepatitis E virus (22, 31). In addition,
preinoculation serum samples were tested for all piglets by PCR for the presence
of PCV1 and PCV2 nucleic acids to confirm that the pigs used in the study were
not naturally infected by either virus (54). The PCV1, PCV2, PCV1-2, and
PCV2-1 infectious DNA clones were all inoculated by direct injection of the
cloned plasmid DNA into the superficial inguinal lymph nodes of pigs as de-
scribed previously (22). Pigs in group 1 received PBS buffer as a negative control.
Group 2 animals were each injected with 200 g of the infectious PCV1 DNA
clone. Group 3 pigs were each injected with 200 g of the infectious PCV2 DNA
clone. Group 4 animals were each injected with 200 g of the chimeric PCV1-2
infectious DNA clone. Group 5 pigs were each injected with 200 g of the
reciprocal chimeric PCV2-1 infectious DNA clone. All animals were monitored
daily for clinical signs of disease. Serum samples were collected from each animal
at 	2, 7, 14, 21, 28, 35, 42, and 49 days postinoculation (dpi). At 21 dpi, four
randomly selected animals from each group were necropsied. The remaining
four animals in each group were necropsied at 49 dpi.
Clinical evaluation. Pigs were weighed on 0 dpi and at the time of necropsies.
Rectal temperatures and clinical respiratory scores, ranging from 0 to 6 (0 

normal; 6 
 severe) (24), were recorded every other day from 0 to 49 dpi.
Clinical observations, including evidence of central nervous system disease, liver
disease (icterus), musculoskeletal disease, and changes in body condition, were
also recorded daily. All clinical evaluations were performed by a team of two
people.
Gross pathology and histopathology. Four pigs from each group were necrop-
sied at 21 and 49 dpi, respectively (only three pigs from group 4 were necropsied
at 21 dpi because one pig died shortly after inoculation). The necropsy team was
blinded to the infection status of the pigs at necropsy. Complete necropsies were
performed on all pigs. An estimated percentage of the lung with grossly visible
pneumonia was recorded for each pig based on a previously described scoring
system (24). Other lesions such as enlargement of lymph nodes (ranging from 0
for normal to 3 for three times normal size) were scored separately. Sections for
histopathologic examination were taken from nasal turbinate, lungs (seven sec-
tions) (24), heart, brain, lymph nodes (tracheobronchial, iliac, mesenteric, sub-
iliac, and superficial inguinal), tonsil, thymus, liver, gall bladder, spleen, joints,
small intestine, colon, pancreas, and kidney. The tissues were examined in a
blinded fashion and given a subjective score for severity of lung, lymph node, and
liver lesions (24). Lung scores ranged from 0 (normal) to 3 (severe lymphohis-
tiocytic interstitial pneumonia). Liver scores ranged from 0 (normal) to 3 (severe
lymphohistiocytic hepatitis). Lymph node scores were for an estimated amount
of lymphoid depletion of follicles ranging from 0 (normal or no lymphoid de-
pletion) to 3 (severe lymphoid depletion and histiocytic replacement of follicles).
Serology. Blood was collected from all pigs at 	2, 7, 14, 21, 28, 35, 42, and 49
dpi. Serum antibodies to PRRSV were assayed using Herd Check PRRSV
enzyme-linked immunosorbent assay (ELISA) (IDEXX Laboratories, West-
brook, Mass.). Serum antibodies to PPV were detected by a hemagglutination
inhibition assay (31). Serum antibodies to PCV2 were detected by a modified
indirect ELISA based on the recombinant ORF2 capsid protein of PCV2 (48).
Serum antibodies to PCV1 were detected by an IFA. Briefly, PK-15 cells infected
with PCV1 were grown on eight-well LabTek chamber slides. When the infected
PK-15 cells reached about 95 to 100% confluency, the cells were fixed with a
solution containing 80% acetone and 20% methanol at 4°C for 20 min. The fixed
cells were washed once with PBS buffer. One hundred microliters of 1:10-diluted
pig serum sample in PBS was added to the chambers and incubated for 1 h at
37°C. The cells were then washed three times with PBS and incubated for 45 min
at 37°C with FITC-labeled goat anti-swine secondary antibody. The slides were
subsequently washed three times with PBS, mounted with Fluoromount-G, cov-
erslipped, and examined under a fluorescence microscope. For the positive
control, PCV1-infected cells were incubated with a diluted PCV1-specific mono-
clonal antibody, followed by an incubation with FITC-labeled goat anti-mouse
immunoglobulin G (Kirkegaard & Perry Laboratories). For the negative control,
PCV1-infected cells were incubated with 1:10-diluted negative swine serum free
of PCV1 or PCV2 antibody, followed by an incubation with FITC-labeled goat
anti-swine immunoglobulin G (Kirkegaard & Perry Laboratories).
PCR. To detect PCV1, PCV2, chimeric PCV1-2, and reciprocal chimeric
PCV2-1 viremia in sera from inoculated pigs, serum samples collected at differ-
ent days postinfection were tested by PCR (Fig. 1). Briefly, viral DNA was
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extracted from 100 l of each serum sample by using DNAzol reagent according
to the manufacturer’s protocol (Molecular Research Center, Cincinnati, Ohio).
The extracted DNA was resuspended in DNase-, RNase-, and proteinase-free
water. To amplify clone-specific genomic sequences of PCV1, PCV2, chimeric
PCV1-2, and reciprocal chimeric PCV2-1, two sets of nested PCR primer pairs
were designed (Table 1). The first set of nested primers was designed based on
published PCV1 sequences. Primers Gen.PCV1 and Orf.PCV1 amplified a
400-bp fragment in the presence of the PCV1 genome. The nested primers,
nested.Gen.PCV1 and nested.Orf.PCV1, amplified a 220-bp fragment.
To detect PCV2 viremia, PCV2 primer pair Gen.PCV2 and Orf.PCV2 ampli-
fied a 900-bp fragment in the presence of PCV2 in the first round of PCR.
Primers nested.Gen.PCV2 and nested.Orf.PCV2 amplified a 600-bp fragment in
the nested PCR.
To detect chimeric PCV1-2 viremia, the first round of PCR employed the
PCV1-specific primer Gen.PCV1 and the PCV2 ORF2-specific primer Orf-
.PCV2 to amplify a chimeric PCV1-2 fragment of 580 bp. For the nested PCR,
the PCV1-specific primer nested.Gen.PCV1 and the PCV2 ORF2-specific
primer nested.Orf.PCV2 were used to amplify a chimeric PCV1-2 fragment of
370 bp.
To detect reciprocal chimeric PCV2-1 viremia, the first round of PCR em-
ployed the PCV2-specific primer Gen.PCV2 and the PCV1 ORF2-specific
primer Orf.PCV1 to amplify a chimeric PCV2-1 fragment of 700 bp. For the
nested PCR, the PCV2-specific primer nested.Gen.PCV2 and the PCV1 ORF2-
specific primer nested.Orf.PCV1 were used to amplify a 460-bp chimeric PCV2-1
fragment.
All PCR parameters were essentially the same, consisting of 38 cycles of
denaturation at 94°C for 1 min, annealing at 45°C for 1 min, and extension at
72°C for 1.5 min. The serum samples from negative-control pigs were tested by
a PCR-restriction fragment length polymorphism diagnostic assay, which can
detect and differentiate both PCV1 and PCV2 as described previously (22).
Sequencing. PCR products from selected animals in each inoculation group,
except for the PCV2-1 group, were sequenced to confirm the origin of the
infecting virus by comparing the sequences recovered from infected pigs to the
sequences of the respective infectious DNA clones with MacVector software
(Oxford Molecular Ltd., Beaverton, Oreg.).
Immunohistochemistry (IHC). IHC detection of PCV2-specific antigen was
performed on lymph nodes collected during necropsies at 21 and 49 dpi. A rabbit
polyclonal antiserum to PCV2 was used for the IHC, according to the procedures
described previously (58). The amount of PCV2 antigen distributed in the lymph
nodes was scored in a blinded fashion by assigning a score of 0 for no signal to
3 for a strong positive signal. The mean scores of inoculation groups were
determined and statistically analyzed. No IHC detection was performed on
PCV1- and PCV2-1-inoculated pig lymph nodes due to an insufficient amount of
the gift PCV1 monoclonal antibody.
RESULTS
The PCV1 clone and PCV1-2 and PCV2-1 chimeric clones
are infectious when transfected into PK-15 cells and express
expected viral capsid antigen. Two identical copies of the com-
plete PCV1 genome were ligated in tandem into the pSK
vector to produce the PCV1 DNA clone (Fig. 1). The infec-
tivity of the PCV1 DNA clone was determined by in vitro
transfection of PK-15 cells. IFA with monoclonal antibody to
the PCV1 ORF2 gene product confirmed that the PCV1 DNA
clone was infectious and that about 10 to 20% of the trans-
fected PK-15 cells were positive for PCV1 capsid antigen in the
nucleus of transfected cells (Fig. 2C).
The infectious PCV2 DNA clone was constructed by ligating
two tandem copies of PCV2 genome into the pSK vector (22)
(Fig. 1). The PCV2 DNA clone was shown to be infectious in
vitro and in vivo in a previous study (22) (Fig. 2F).
The chimeric PCV1-2 DNA clone had the ORF2 capsid
gene of PCV1 replaced by that of the pathogenic PCV2 in the
backbone of the nonpathogenic PCV1 genome. The infectivity
of the PCV1-2 chimeric DNA clone was determined by in vitro
transfection of PK-15 cells. Therefore, the chimeric PCV1-2
DNA clone should, if infectious in vitro, have replicated and
produced the ORF2 capsid antigen of PCV2. IFA with anti-
bodies to PCV2 confirmed that the PCV1-2 DNA clone was
infectious and that about 10 to 20% of the transfected PK-15
cells were positive for PCV2 antigen within the nucleus of
infected cells (Fig. 2H).
The reciprocal chimeric PCV2-1 DNA clone had the ORF2
capsid gene of PCV2 replaced by that of the nonpathogenic
PCV1 in the backbone of the pathogenic PCV2 genome.
Therefore, the reciprocal chimeric PCV2-1 DNA clone should
have replicated and expressed PCV1 ORF2 capsid antigen in
transfected PK-15 cells, if it was infectious. IFA with PCV1
ORF2-specific monoclonal antibody showed that the PCV2-1
chimeric DNA clone was infectious and that about 10 to 20%
of the transfected PK-15 cells expressed PCV1 ORF2 antigen
in the nucleus of transfected cells (Fig. 2I).
In vitro characterization of PCV1, PCV2, PCV1-2, and
PCV2-1 infectious DNA clones. To confirm the viability of the
progeny viruses after initial transfection and to compare the in
vitro replication levels of the four viruses, four synchronized
PK-15 cell cultures were transfected with 44 g each of PCV1,
PCV2, PCV1-2, or PCV2-1 infectious DNA clones. The infec-
tious titers of the initial transfected cell cultures for all four
infectious DNA clones ranged from 104.33 to 105 50% tissue
culture infective doses (TCID50)/ml (Fig. 3), indicating that
PCV1, PCV2, PCV1-2, and PCV2-1 infectious DNA clones all
gave rise to similar numbers of progeny viruses after initial
transfection. The infectious virus titers fluctuated within 1 log
during five serial passages (Fig. 3).
To further determine the growth characteristics of the four
viruses, a one-step growth curve was performed simultaneously
for each virus. Samples were collected at 12-h intervals from
cells infected with either PCV1, PCV2, PCV1-2, or PCV2-1
virus stock at an MOI of 0.1. The infectious titers for each virus
at different time points were determined by IFA (Fig. 4). The
initial titers after infection at 12 h postinoculation were about
101.5 TCID50/ml for all four viruses. The infectious titers in-
creased from 12 to 96 h for all four viruses. By 96 h postinfec-
tion, PCV1 had a titer of 104.33 TCID50/ml, while PCV2,
PCV1-2, and PCV2-1 infectious titers ranged from 102.66 to
102.33 TCID50/ml.
Immunogenicity of PCV1, PCV2, chimeric PCV1-2, and
PCV2-1 infectious DNA clones in pigs. Serum samples col-
lected from all control and inoculated animals at 	2, 7, 14, 21,
28, 35, 42, and 49 dpi were assayed for PCV1, PCV2, PCV1-2,
and PCV2-1 viremia by PCR detection of clone-specific DNA
sequences; for anti-PCV1 antibody by IFA; and for anti-PCV2
ORF2 antibody by ELISA. Prior to inoculation at 	2 dpi,
animals from all five groups tested negative by PCR for both
PCV1 and PCV2 nucleic acids.
Negative-control animals were negative for both PCV1 and
PCV2 viremia throughout the study (Table 2). Five pigs in the
uninoculated control group had detectable PCV2 maternal
antibody at 	2 dpi, and two pigs had detectable PCV1 mater-
nal antibodies at 7 dpi (Table 3). The maternal antibodies to
both PCV1 and PCV2 in these piglets waned by 21 dpi. No
seroconversion to antibodies of either PCV1 or PCV2 was
detected in any of the eight uninoculated control pigs through-
out the study.
In the PCV1-inoculated group, viremia was first detected in
an inoculated pig at 7 dpi (Table 2) and was last detected at 35
11236 FENAUX ET AL. J. VIROL.
dpi. Five out of eight animals inoculated with the PCV1 infec-
tious DNA clone were positive for PCV1 viremia. The average
length of continuous PCV1 viremia was 0.625 weeks. By 21 dpi,
all animals in the PCV1-inoculated group had seroconverted to
PCV1 antibodies and remained positive for anti-PCV1 anti-
bodies until the end of the study at 49 dpi.
It was previously shown that the PCV2 DNA clone is infec-
tious in pigs (22). In the PCV2 DNA clone-inoculated group,
PCV2 viremia was first detected at 7 dpi (Table 2). By 21 dpi,
all PCV2-inoculated group 3 animals were positive for PCV2
viremia. The average length of PCV2 viremia was 2.12 weeks.
Two pigs in the PCV2-inoculated group had detectable low
levels of maternal PCV2 antibodies (optical density at 405 nm
[OD405], 0.4) at 7 dpi (Table 3), and the maternal antibodies
in these piglets waned by 14 dpi. Seroconversion to antibodies
of PCV2, assayed by a PCV2-specific ELISA, was first detected
FIG. 2. The PCV1, PCV2, chimeric PCV1-2, and reciprocal chimeric PCV2-1 DNA clones were infectious and expressed respective viral
antigens when transfected in vitro in PK-15 cells. The left panels (A, C, E, G, and I) were stained with monoclonal antibody to the PCV1 ORF2.
The right panels (B, D, F, H, and J) were stained with antibody to PCV2. (A and B) Mock-transfected PK-15 cells. (C and D) PK-15 cells
transfected with the PCV1 DNA clone. (E and F) PK-15 cells transfected with the PCV2 DNA clone. (G and H) PK-15 cells transfected with the
chimeric PCV1-2 DNA clone. (I and J) PK-15 cells transfected with the reciprocal chimeric PCV2-1 DNA clone.
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at 35 dpi. By 42 dpi, all pigs inoculated with the PCV2 infec-
tious DNA clone had seroconverted to antibodies of PCV2.
In group 4 pigs inoculated with the PCV1-2 chimeric infec-
tious DNA clone, viremia specific for the chimeric PCV1-2
virus was first detected at 14 dpi (Table 2). Four out of seven
inoculated animals became viremic for PCV1-2 between 14
and 42 dpi. The average length of chimeric PCV1-2 viremia
was 1 week. One pig had detectable low levels of maternal
PCV2 antibodies at 7 and 14 dpi (OD405, 0.4), but the ma-
ternal antibody waned by 21 dpi (Table 3). Seroconversion to
PCV2 ORF2-specific antibody first occurred at 28 dpi. By 49
dpi, all pigs inoculated with chimeric PCV1-2 infectious DNA
clone had seroconverted to PCV2 ORF2-specific antibody.
In pigs inoculated with the reciprocal chimeric PCV2-1
DNA clone, viral DNA specific for PCV2-1 chimeric virus was
not detected in serum samples (Table 2). However, by 21 dpi,
all animals in group 5 seroconverted to anti-PCV1 antibody.
PCR products amplified from selected pigs in groups 2, 3,
and 4 were sequenced and confirmed to be the authentic re-
spective infectious DNA clones used in the inoculation for
each group (data not shown). No PCR product from group 5
animals injected with the PCV2-1 reciprocal chimeric clone
was sequenced since we were unable to detect viremia.
Pathogenicity of PCV1, PCV2, chimeric PCV1-2, and recip-
rocal chimeric PCV2-1 infectious DNA clones in pigs. (i) Clin-
ical evaluation. As expected, none of the control or inoculated
pigs showed signs of PMWS (wasting, pneumonia, or icterus).
There were no differences in weight gain or mean rectal tem-
peratures among any of the groups (data not shown). One of
the pigs from PCV1-2-inoculated group 4 was found dead on
the morning following inoculation. No pathogenic agents were
detected, lesions consistent with infectious disease were lack-
ing, and it was concluded that the death was not associated
with the inoculation procedure or the chimeric PCV1-2 virus.
(ii) Gross lesions. Pigs in the four inoculated groups 2 to 5
had various degrees of gross lesions limited to the lymph nodes
(Table 4). Lymph nodes of animals from the uninoculated
control group 1 were normal at both 21 and 49 dpi (Table 4).
In PCV1-inoculated group 2 pigs, lymph nodes were grossly
normal at 21 dpi; however, mild to moderate enlargement of
all lymph nodes was detected at 49 dpi. All PCV2-inoculated
FIG. 3. In vitro transfection of PK-15 cells with PCV1, PCV2,
PCV1-2, and PCV2-1 DNA clones followed by five serial passages of
the four viruses in PK-15 cells. Synchronized PK-15 cells were trans-
fected each with 44 g of the PCV1, PCV2, PCV1-2, or PCV2-1 DNA
clone. The PCV1, PCV2, PCV1-2, and PCV2-1 clones had similar
infectious viral titers after the initial transfection. The infectious titers
were determined at each passage according to the Ka¨ber method.
FIG. 4. One-step growth curve of PCV1, PCV2, PCV1-2, and
PCV2-1 viruses. Synchronized PK-15 cell cultures were each infected
with PCV1, PCV2, PCV1-2, or PCV2-1 virus, all at an MOI of 0.1. All
four viruses had a titer of about 101.5 TCID50/ml at 12 h postinocula-
tion. PCV1 replicated more efficiently in vitro than did PCV2, PCV1-2,
and PCV2-1 viruses.
TABLE 2. Detection of viremia by nested PCR in sera of
inoculated and control pigs
Group Inoculuma
No. of pigs positive/no. testedb
No. at dpt:
Total
	2 7 14 21 28 35 42 49
1 PBS 0/8 0/8 0/8 0/8 0/4 0/4 0/4 0/4 0/8
2 PCV1 DNA 0/8 1/8 1/8 2/8 0/4 2/4 0/4 0/4 5/8
3 PCV2 DNA 0/8 3/8 6/8 7/8 1/4 2/4 2/4 0/4 8/8
4 PCV1-2 DNA 0/8 0/7 1/7 2/7 2/4 2/4 2/4 0/4 4/7
5 PCV2-1 DNA 0/8 0/8 0/8 0/8 0/4 0/4 0/4 0/4 0/8
a PBS used as negative control. Cloned genomic PCV or chimeric PCV DNA
in the pSK plasmid.
b Eight pigs in each group; one pig died in group 4 shortly after inoculation.
TABLE 3. Seroconversion to PCV2 antibodies in pigs inoculated
with PCV2 or chimeric PCV1-2 infectious DNA clones and
seroconversion to PCV1 antibodies in pigs inoculated with PCV1 or
reciprocal chimeric PCV2-1 infectious DNA clones
Group Inoculuma Antibody forwhich testedb
No. of pigs positive/no. tested at dpic:
	2 7 14 21 28 35 42 49
1 PBS PCV1 NAd 2/8 2/8 1/8 0/4 0/4 0/4 0/4
PCV2 5/8 5/8 2/8 0/8 0/4 0/4 0/4 0/4
2 PCV1 DNA PCV1 ORF2 NA 3/8 2/8 8/8 4/4 4/4 4/4 4/4
3 PCV2 DNA PCV2 3/8 2/8 0/8 0/8 0/4 3/4 4/4 4/4
4 PCV1-2 DNA PCV2 2/8 1/7 1/7 0/7 1/4 1/4 3/4 4/4
5 PCV2-1 DNA PCV1 ORF2 NA 3/8 3/8 7/8 3/4 3/4 4/4 4/4
a PBS used as a negative control. The inocula were infectious DNA clones in
the pSK plasmid.
b PCV1 antibody to ORF2 was measured with an IFA specific for PCV1 ORF2
antigen. PCV2 antibody was measured with an ELISA.
c One pig in group 4 died shortly after inoculation.
d NA, not applicable.
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group 3 pigs had enlarged tan lymph nodes two to five times
the normal size, at both 21 and 49 dpi. Lymph nodes from
chimeric PCV1-2-inoculated animals were mildly to moder-
ately enlarged and tan at both 21 and 49 dpi in five out of seven
pigs (Table 4). In group 5 pigs, inoculated with the PCV2-1
clone, one out of eight animals had mildly enlarged and tan
lymph nodes at 21 dpi (Table 4). The average scores of gross
lesions of the lymph nodes in pigs inoculated with the chimeric
PCV1-2 clone were not statistically different from those in
groups 1, 2, and 5 but were significantly different (P  0.05)
from those of the pathogenic PCV2-inoculated group 3 pigs at
21 dpi. Average lymph node gross lesion scores at 49 dpi from
the PCV1-, PCV2-, and PCV1-2-inoculated animals were not
significantly different from each other but were all statistically
different (P  0.05) from the average gross lesion scores of
group 1 and 5 pigs (Table 4).
(iii) Microscopic lesions. No microscopic lesions were de-
tected in either uninoculated control group 1 pigs or PCV1-
inoculated group 2 pigs at any day postinfection (Table 5).
Microscopic lung lesions characterized as mild peribronchiolar
lymphoplasmacytic and histiocytic bronchointerstitial pneumo-
nia (Table 5) were observed in one out of the eight PCV2-
inoculated pigs. In the PCV1-2- and PCV2-1-inoculated ani-
mals, no microscopic lesions were observed in the lungs. No
lesions were observed in the thymuses of any inoculated pigs
(Table 5). Mild multifocal lymphoplasmacytic myocarditis was
observed in two of eight pigs in the PCV2-inoculated group
(Table 5). Heart tissues from PCV1-2- and PCV2-1-inoculated
animals were free of microscopic lesions. Mild multifocal lym-
phoplasmacytic interstitial nephritis was observed in four out
of eight pigs in the PCV2-inoculated group, in two out of seven
PCV1-2-inoculated pigs, and in one out of eight PCV2-1-inoc-
ulated pigs (Table 5). Mild to moderate lymphoid depletion
and histiocytic replacement of follicles were observed in the
tonsil in five out of eight pigs, in the spleen in three out of eight
pigs, and in the lymph nodes in eight out of eight pigs in the
PCV2-inoculated group. In the chimeric PCV1-2-inoculated
animals, mild lymphoid depletion and histiocytic replacement
of follicles were observed in the lymph nodes of two out of
seven pigs but were not detected in either the spleen or tonsils.
No lymphoid depletion and histiocytic replacement of follicles
were observed in the lymph nodes, spleen, or tonsils of the
reciprocal chimeric PCV2-1-inoculated animals (Table 5).
Mild to moderate lymphoplasmacytic hepatitis was observed in
seven out of the eight PCV2-inoculated pigs. Mild lymphop-
lasmacytic hepatitis was observed in two out of the seven chi-
meric PCV1-2-inoculated pigs. No lymphoplasmacytic hepati-
tis was observed in reciprocal chimeric PCV2-1-inoculated pigs
(Table 5). Lesions in other tissues were unremarkable, except
for one animal inoculated with PCV2 that showed mild micro-
scopic lesions in the brain.
Microscopic lesions in the lung, liver, and lymph nodes were
scored according to a published scoring system (24). Mean
scores of lesions in lymph nodes in pigs from the chimeric
PCV1-2-inoculated group 4 were similar to those from groups
1, 2, and 5 but were significantly different (P  0.05) from
those of the pathogenic PCV2-inoculated group 3 pigs, at both
21 and 49 dpi (Table 5). Mean microscopic liver lesion scores
from the chimeric PCV1-2-inoculated group at 21 dpi were
significantly different (P  0.05) from those of PCV2-inocu-
lated group 3 animals but were similar to those of group 1, 2,
and 5 pigs at 21 dpi. At 49 dpi, the mean microscopic liver
scores from group 4 chimeric PCV1-2-inoculated pigs were not
statistically different from those of group 1, 2, 3, and 5 pigs.
TABLE 4. Gross lymph node lesions in control and inoculated pigs
Group Inoculuma
No. of pigs with enlarged lymph
nodes/no. necropsied at each dpi-
(mean score for estimated
enlargement)b
21 49
1 PBS 0/4 (0.0)I 0/4 (0.0)I
2 PCV1 DNA 0/4 (0.0)I 4/4 (1.5)II
3 PCV2 DNA 4/4 (2.5)II 4/4 (2.25)II
4 PCV1-2 DNA 2/3 (0.66)I 3/4 (1.25)II
5 PCV2-1 DNA 1/4 (0.25)I 0/4 (0.0)I
a PBS used as a negative control. The inocula were infectious DNA clones in
the pSK plasmid.
b Four pigs from each group were necropsied at 21 dpi and the remaining pigs
were necropsied at 49 dpi. Different superscripts (I and II) within each column
indicate significantly different mean value scores between groups.
TABLE 5. Distribution of histopathological lesions in different tissues and organs from control and inoculated pigs
Group Inoculuma dpib
No. of pigs positive/no. tested
Lungc Liverc Lymphnodesc Spleen Thymus Ileum Brain Heart Kidney Tonsil
1 PBS 21 0/4 (0.0)I 0/4 (0.0)I 0/4 (0.0)I 0/4 0/4 0/4 0/4 0/4 0/4 0/4
49 0/4 (0.0)I 0/4 (0.0)I 0/4 (0.0)I 0/4 0/4 0/4 0/4 0/4 0/4 0/4
2 PCV1 DNA 21 0/4 (0.0)I 0/4 (0.0)I 0/4 (0.0)I 0/4 0/4 0/4 0/4 0/4 0/4 0/4
49 0/4 (0.0)I 0/4 (0.0)I 0/4 (0.0)I 0/4 0/4 0/4 0/4 0/4 0/4 0/4
3 PCV2 DNA 21 0/4 (0.0)I 4/4 (1.5)II 4/4 (1.75)II 3/4 0/4 0/4 1/4 1/4 2/4 3/4
49 1/4 (0.25)I 3/4 (0.75)II 4/4 (1.0)II 0/4 0/4 0/4 0/4 1/4 2/4 2/4
4 PCV1-2 DNA 21 0/3 (0.0)I 1/3 (0.33)I 1/3 (0.33)I 0/3 0/3 0/3 0/3 0/3 0/3 0/3
49 0/4 (0.0)I 1/4 (0.25)I,II 1/4 (0.25)I 0/4 0/4 0/4 0/4 0/4 2/4 0/4
5 PCV2-1 DNA 21 0/4 (0.0)I 0/4 (0.0)I 0/4 (0.0)I 0/4 0/4 0/4 0/4 0/4 0/4 0/4
49 0/4 (0.0)I 0/4 (0.0)I 0/4 (0.0)I 0/4 0/4 0/4 0/4 0/4 1/4 0/4
a PBS was used as a negative control. The inocula were infectious DNA clones in the pSK plasmid.
b Four pigs from each group were necropsied at 21 dpi, and the remaining pigs were necropsied at 49 dpi.
c Values in parentheses are mean histological scores (0, normal; 1, mild; 2, moderate; 3, severe) for interstitial pneumonia for lung, hepatitis for liver, and lymphoid
depletion for lymph nodes. Different superscripts (I and II) within each column indicate significantly different mean value scores between groups.
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(iv) Detection of PCV antigen. IHC staining of PCV2-spe-
cific antigen was performed on lymph nodes of all pigs nec-
ropsied at 21 and 49 dpi. As expected, lymph nodes from the
uninoculated control and PCV1- and PCV2-1-inoculated pigs
were negative for PCV2 antigen. PCV2 antigen was detected in
lymphoid tissues of four out of four animals in the PCV2-
inoculated group at 21 dpi and in three out of four animals at
49 dpi. PCV2 antigen was also detected in lymphoid tissue of
one out of four pigs from the chimeric PCV1-2-inoculated
group at 49 dpi, but no PCV2 antigen was detected in lymphoid
tissues of PCV1-2-inoculated animals at 21 dpi (Table 6). At 21
dpi, the mean scores for the estimated level of PCV2 antigen
in PCV1-2-inoculated animals were significantly different (P 
0.05) from those for PCV2-inoculated pigs but were not sig-
nificantly different from those for the control group 1. At 49
dpi, the mean IHC score of the PCV1-2-inoculated animals
was not significantly different from that of the PCV2-inocu-
lated group 3 or the control group 1.
DISCUSSION
PMWS has become a major global swine disease. It has
become a serious economic problem for the swine industry,
and there is an urgent need to develop a vaccine against PCV2,
the primary causative agent of PMWS. We report here, for the
first time, the construction and characterization of a chimeric
PCV1-2 infectious DNA clone and demonstrate that the chi-
meric PCV1-2 infectious clone induces an immune response
specific to the pathogenic PCV2 immunogenic ORF2 capsid
protein while it is attenuated in SPF pigs. Animals inoculated
via intralymphoid injections with the chimeric PCV1-2 infec-
tious DNA clone developed a mild infection resembling that of
PCV1-inoculated animals while seroconverting to antibody of
the ORF2 capsid protein of the pathogenic PCV2. The average
length of viremia observed in PCV1- and chimeric PCV1-2-
inoculated animals was shorter, 0.625 and 1 week, respectively,
than that in pathogenic PCV2-inoculated animals, which was
about 2.12 weeks. The lack of detectable chimeric PCV1-2
viremia in sera or viral antigen in lymphoid tissues in some of
the inoculated animals did not affect seroconversion to anti-
body of PCV2 ORF2 capsid protein, as all pigs in PCV1-2-
inoculated group 4 pigs had seroconverted. The results sug-
gested that, even though the chimeric PCV1-2 viremia and
viral antigen were undetectable in some inoculated animals,
chimeric PCV1-2 virus was still able to induce an antibody
response to PCV2 ORF2 capsid protein. Similarly, none of the
PCV2-1-inoculated pigs had detectable viremia, but they all
seroconverted to anti-PCV1 capsid antibody by 49 dpi. The
lack of viremia or viral antigen in some PCV1-2-inoculated
pigs and the lack of viremia in PCV2-1-inoculated pigs could
be due to a lower replication level of the PCV1-2 and PCV2-1
chimeric viruses in pigs. The one-step growth curve results
indicated that PCV1-2 and PCV2-1 chimeric viruses had sim-
ilar in vitro growth patterns, comparable to that of the wild-
type PCV2. Thus, PCV2-1 and PCV1-2 are viable infectious
DNA clones capable of producing infectious virions in vitro.
We found that PCV1 replicated more efficiently than PCV2,
PCV1-2, and PCV2-1 in PK-15 cells. This is likely due to the
fact that the PCV1 isolate used in this study originated from
the PK-15 cell line and thus may have already adapted to
replicate in the PK-15 cells. After the initial transfection which
produced similar infectious virions for all four viruses, the
serially passaged PCV1, PCV2, PCV1-2, and PCV2-1 viruses
replicated well in PK-15 cells, although the two chimeric vi-
ruses replicated slightly less efficiently in vitro.
The presence of low levels of maternal antibodies in some
pigs did not seem to have any confounding influences on the
onset of viremia or seroconversion. Since only a few animals in
each experimental group had low levels of maternal antibodies
at the time of inoculation, we were unable to make a definitive
assessment as to whether low levels of maternal antibodies
could prevent infection. However, a recent study by Harms et
al. (29) showed that a PCV2 maternal antibody titer of an
OD405 of 0.6 or above is required to prevent PCV2 replication.
The highest maternal antibody titer detected in this study was
an OD405 of 0.4 in only one pig, and all other pigs with ma-
ternal antibodies had very low titers (OD405 of 0.4) at the
time of inoculation.
It is known that PCV2 replicates in the lymph nodes, lungs,
and liver and that one of the major pathogenic effects is the
impairment of the immune system by degradation of the lym-
phoid structures (10, 11, 20, 27, 33, 68). Gross lesions affecting
the lymph nodes in both the nonpathogenic PCV1- and the
chimeric PCV1-2-inoculated pigs were mild and limited to only
a few pigs, whereas the pathogenic PCV2-inoculated pigs all
had moderate to severe enlargement and discoloration of
lymph nodes (Table 4). The gross lymph node lesions found in
PCV1-inoculated pigs at 49 dpi are likely nonspecific, which is
sometimes seen in pigs, and are not induced by PCV1, since no
microscopic lesions in the lymph nodes were found in these
same animals at 49 dpi. Statistical analysis revealed that the
scores of the gross lesions in the lymph nodes of the chimeric
PCV1-2-inoculated animals were similar to those in nonpatho-
genic PCV1-inoculated pigs. At 21 dpi, PCV2-inoculated pigs
had gross lesions that were significantly (P 0.05) more severe
than those of the PCV1- and of the chimeric PCV1-2-inocu-
lated pigs. Microscopically, at both 21 and 49 dpi, the chimeric
PCV1-2-inoculated animals had significantly (P  0.05) fewer
and less severe microscopic lesions than did the PCV2-inocu-
lated animals. The microscopic lesion scores in lymph nodes of
the chimeric PCV1-2-inoculated pigs were similar to those of
the nonpathogenic PCV1-inoculated pigs, the reciprocal chi-
meric PCV2-1-inoculated pigs, and the uninoculated control
animals. IHC detection of PCV2 antigen within the lymph
nodes from inoculated animals showed that the mean score of
TABLE 6. Immunohistochemical detection of PCV2 antigen in
lymph nodes of control and PCV2- and PCV1-2-inoculated pigs
Group Inoculuma
No. of pigs positive/no. tested at dpib:
21 49
1 PBS 0/4 (0  0.00)I 0/4 (0  0.00)I
3 PCV2 DNA 4/4 (2  0.67)II 3/4 (0.75  0.25)II
4 PCV1-2 DNA 0/3 (0  0.00)I 1/4 (0.25  0.25)I,II
a PBS was used as a negative control. The inocula were infectious DNA clones
in the pSK plasmid.
b Four pigs from each group were necropsied at 21 dpi, and the remaining pigs
were necropsied at 49 dpi. Values in parentheses are the mean estimated levels
of PCV2 antigen in lymphoid tissue (ranging from 0, no antigen detected, to 3,
high levels of antigen). Different superscripts within each column (I and II)
indicate significantly different mean value scores between groups.
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PCV2 antigen in PCV2-inoculated animals was significantly
more intense (P  0.05) than that from PCV1-2-inoculated
animals, suggesting that during PCV1-2 replication in vivo
there is a reduced level of antigen presence within the lym-
phoid tissues, the main target tissue of pathogenic PCV2. Mild
to moderate lesions were found in multiple tissues of patho-
genic PCV2-inoculated animals including lungs, liver, lym-
phoid tissues, spleen, brain, heart, kidneys, and tonsil tissue.
However, in the chimeric PCV1-2-inoculated animals, mild to
moderate microscopic lesions were limited to only liver, lymph
nodes, and kidney tissues (Table 5). The microscopic liver
lesion score at 21 dpi in chimeric PCV1-2-inoculated pigs was
significantly less severe (P  0.05) than that of PCV2-inocu-
lated animals. However, at 49 dpi the microscopic liver lesion
scores in both PCV2- and PCV1-2-inoculated animals were not
significantly different (P  0.05). It is important, however, that
the microscopic liver lesion score of chimeric PCV1-2-inocu-
lated animals at 49 dpi was also not significantly different (P 
0.05) from the scores of PCV1- and PCV2-1-inoculated pigs
and of the negative-control pigs (Table 5). Recent studies
showed that the pathological lesions in PCV2-infected pigs
generally peak at about 21 to 28 dpi (53; Opriessnig et al.,
submitted), and this could explain why there was no significant
difference in liver lesion scores at 49 dpi.
A previous study showed that the infectious PCV2 DNA
clone induced pathological lesions characteristic of PMWS but
did not induce clinical PMWS (22). It is generally believed that
PCV2 is the primary, but not the sole, pathogenic agent re-
sponsible for the onset of clinical PMWS. In most experimen-
tal models to date, clinical PMWS was reproduced only in SPF
pigs coinfected with PCV2 and either PPV or PRRSV (57;
Opriessnig et al., submitted) or in PCV2-inoculated gnotobi-
otic pigs when their immune system was activated by keyhole
limpet hemocyanin in incomplete Freund’s adjuvant (35) or
administration of bacterins (6). In cases of a PRRSV-PCV2
coinfection, the PMWS characteristic pathological signs such
as lymphoid depletion, granulomatous inflammation, and ne-
crotizing hepatitis were induced by PCV2 and not by PRRSV
(28). Field studies continue to indicate a reduction of PMWS
cases when piglets in herds in which PMWS is endemic and
with PPV circulation are vaccinated against PPV (25). How-
ever, under laboratory conditions, upon challenge with PCV2,
PPV vaccination of SPF pigs failed to decrease the occurrence
of PMWS lesions compared to that for unvaccinated animals
(Opriessnig et al., submitted). Therefore, vaccinations against
PPV and possibly PRRSV, and thus limitation of the infections
caused by them, may not prevent the onset of PMWS in PCV2-
infected pigs, and a vaccine against PCV2 and PMWS is
needed.
The availability of the PCV2, PCV1, chimeric PCV1-2, and
reciprocal chimeric PCV2-1 infectious DNA clones enables us
to study the structural and functional relationships of PCV
genes. In this study, we swapped the immunogenic ORF2 cap-
sid gene between the pathogenic PCV2 and the nonpathogenic
PCV1 and showed that the chimeric PCV1-2 infectious DNA
clone replicated and expressed the immunogenic ORF2 capsid
antigen of PCV2 in vitro and in vivo and induced a specific
antibody response to PCV2 ORF2 but retained the nonpatho-
genic nature of PCV1. Therefore, the chimeric PCV1-2 infec-
tious DNA clone developed in this study could serve as a useful
vaccine candidate against PCV2 infection and PMWS. The
chimeric PCV1-2 infectious DNA clone has the ability to in-
duce a strong immune response against PCV2 while inducing
only a limited infection with mild pathological lesions, low
levels of viremia, and low or nondetectable levels of viral an-
tigen in lymphoid tissues, similar to infection by the nonpatho-
genic PCV1. The average ELISA OD405 values at 49 dpi were
0.511 (with 0.2 as the cutoff) for the remaining four seroposi-
tive pigs in the chimeric PCV1-2 group, 0.807 for the remaining
four seropositive pigs in the PCV2 group, and 0.046 for the
remaining four seronegative pigs in the negative-control group.
Therefore, the chimeric PCV1-2 infectious DNA clone in-
duced a relatively high anti-PCV2 antibody response compa-
rable to that for PCV2. Future studies are warranted to deter-
mine if the PCV2 ORF2-specific antibody response induced by
the chimeric PCV1-2 infectious DNA clone can protect pigs
against challenge with wild-type pathogenic PCV2. The rela-
tively easy storage and stability of cloned DNA and the econ-
omy of large-scale chimeric PCV1-2 DNA clone production
should provide an attractive means of delivering a live infec-
tious viral DNA vaccine to pigs. However, the intralymphoid
route of inoculation used in this study is not practical for
vaccine delivery, and thus, future studies will determine if pigs
can be infected by alternate routes such as intramuscular in-
jection of the chimeric PCV1-2 infectious DNA clone. The
intramuscular and intradermal routes of inoculation have been
successful in other studies with viral infectious DNA clones
(59, 69).
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